Dr. Wong on an Investigational Antibody-Drug Conjugate in Multiple Myeloma

Video

In Partnership With:

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

The ADC (GSK2857916) is being developed by GlaxoSmithKline. It has been studied in a phase I, first-in-human trial that was presented at the 2017 ASH Annual meeting. In the dose-escalation phase, there were no dose-limiting toxicities, says Wong. Patients in the trial were very heavily pretreated; many of them had received at least 5 prior lines of therapy and were refractory to immunomodulatory agents, proteasome inhibitors, and daratumumab (Darzalex). Despite that, the response rates were impressive at around 60%.

Based on those data, the FDA granted a breakthrough therapy designation to the agent for the treatment of patients who have failed at least 3 prior lines of therapy, including an anti-CD38 antibody and are refractory to a proteasome inhibitor and an immunomodulatory (IMiD) agent. Some hematologic as well as ocular toxicities were observed, including grade 3 dry eyes, corneal keratitis, and eye pain.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD